• Strategic combination unites Cardioline’s global reach and proven cardiac technology with Cardios’s decades of clinical expertise in Holter monitoring and ABPM

Cardioline, a globally recognised leader in cardiac diagnostics and a pioneer in Telecardiology, delivering connected, remote cardiac care solutions to clinicians and patients across more than 85 countries, today announced the successful acquisition of Cardios (São Paulo, Brazil) from Halma. Cardios is a highly respected innovator in Holter monitoring and ambulatory blood pressure monitoring (ABPM) with a decades-long track record of clinical reliability in Brazil. The transaction, supported by ARCHIMED, marks a transformative milestone for both organisations, accelerating Cardioline’s telecardiology strategy and signalling a new chapter in the advancement of comprehensive, connected, and patient-centred cardiac diagnostics worldwide.

The acquisition brings together two organisations whose complementary strengths span the full cardiac diagnostic journey. Cardioline’s already internationally established full portfolio will be further complemented with Cardios’s specialised regional expertise in Holter and ABPM technologies. Together, the combined entity is positioned to deliver a broader, more integrated suite of cardiac diagnostic solutions to physicians, healthcare institutions, and patients across global markets.

ARCHIMED, the specialist healthcare private equity firm and majority shareholder of Cardioline, played a central role in enabling this transaction. The acquisition reflects ARCHIMED’s continued commitment to building leading, scaled platforms in medtech and healthcare services, and furthers Cardioline’s growth strategy under ARCHIMED’s ownership. This milestone equally reflects the strong foundation that Halma has built at Cardios over the years; their stewardship has produced a business of exceptional clinical quality and commercial strength, and Cardioline is proud to continue building on that legacy.

“This acquisition is an exciting moment for Cardioline and a clear expression of our vision: to power a better cardiac care globally. Cardios has earned an exceptional reputation for precision and reliability over decades, and their deep expertise in Holter and ABPM is the perfect complement to our global portfolio. Together, we are creating a truly end-to-end solution that supports every step of the cardiac care pathway.
This transaction also significantly strengthens Cardioline’s leadership position in telemedicine. Beyond the product synergies, this acquisition opens a meaningful new geographic hub for Cardioline, expanding our presence and commercial reach into markets where Cardios has built strong, trusted relationships. This is precisely the kind of strategic growth, clinically grounded, geographically expansive, and deeply aligned in values, that we set out to achieve with the support of ARCHIMED. We are proud to welcome the Cardios team into the Cardioline family.” — Luis Meireles, CEO, Cardioline

“This integration represents a strategic leap for Cardios’s portfolio, which now incorporates Cardioline’s proven solutions, specifically in stress test systems and electrocardiography, increasing our capability to offer a complete care across the clinical journey. By combining Cardioline’s global reach with the clinical expertise, market proximity, and the reliability built by Cardios in Holter and ABPM over decades, we strengthen our shared goal of redefining standards in cardiac diagnostics and generating a positive, lasting impact for physicians, healthcare institutions, and patients. Together we may transform innovation into solutions that make the difference saving lives” — Erica Chriguer, Cardios